{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T07:40:23Z","timestamp":1792309223859,"version":"4.4.0"},"reference-count":98,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"indian council of medical research","doi-asserted-by":"publisher","award":["2022-03035"],"award-info":[{"award-number":["2022-03035"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:p>Prostate cancer (PCa) remains a leading cause of cancer-related morbidity and mortality among men worldwide, with advanced stages often exhibiting resistance to standard therapies. Drug resistance in advanced prostate cancer is a multifactorial process influenced by genetic mutations, hereditary factors, epigenetic alterations, lifestyle choices, and dietary habits. Understanding this complex interplay is crucial for developing effective predictive and therapeutic strategies. In this context, a multiomics approach integrating genomics, transcriptomics, proteomics, metabolomics, and epigenomics offers a comprehensive framework to dissect the molecular mechanisms driving drug resistance.<\/jats:p>\n                  <jats:p>Current challenges include tumor heterogeneity, limited access to longitudinal patient data, and insufficient representation of diverse populations in omics datasets. This study highlights the novel application of multiomics integration to stratify patient subgroups based on molecular signatures, enabling early prediction of therapy resistance. We also emphasize key biomarkers and signaling pathways associated with treatment failure, including alterations in androgen receptor signaling, PI3K-AKT-motor pathways, and metabolic rewiring. The integration of these datasets not only enhances diagnostic precision but also aids in identifying actionable therapeutic targets. It also opens up new avenues for developing targeted therapies by integrative profiling and quantifying a broad spectrum of biomolecular features across distinct subtypes of malignant cells.<\/jats:p>","DOI":"10.1177\/03915603261457521","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:40:27Z","timestamp":1782718827000},"page":"713-729","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Multiomics empowers predictive drug resistance in advanced prostate cancer"],"prefix":"10.1177","volume":"93","author":[{"given":"Abhimanyu","family":"Agrawal","sequence":"first","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bathinda, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archit","family":"Goel","sequence":"additional","affiliation":[{"name":"All India Institute of Medical Sciences (AIIMS), Bathinda, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh Kumar","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences (AIIMS), Bathinda, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6002-810X","authenticated-orcid":false,"given":"Mintu","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bathinda, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_3_3_2","unstructured":"Ferlay J Laversanne M Ervik M et al. Global Cancer Observatory: Cancer Today. Lyon France: International Agency for Research on Cancer. Available from: https:\/\/gco.iarc.fr\/today (2021 accessed 3 October 2025)."},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","unstructured":"Siegel RL Miller KD Jemal A. Cancer statistics 2020. CA Cancer J Clin 2020; 70(1): 7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","DOI":"10.3322\/caac.21590"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","unstructured":"Shen MM Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010; 24(18): 1967\u20132000. https:\/\/doi.org\/10.1101\/gad.1965810","DOI":"10.1101\/gad.1965810"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","unstructured":"Haffner MC Zwart W Roudier MP et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol 2021; 18(2): 79\u201392. https:\/\/doi.org\/10.1038\/s41585-020-00400-w","DOI":"10.1038\/s41585-020-00400-w"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","unstructured":"Gillessen S Attard G Beer TM et al. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019. Eur Urol 2020; 77(4): 508\u2013547. https:\/\/doi.org\/10.1016\/j.eururo.2020.01.012","DOI":"10.1016\/j.eururo.2020.01.012"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"Watson PA Arora VK Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 2015; 15(12): 701\u2013711. https:\/\/doi.org\/10.1038\/nrc4016","DOI":"10.1038\/nrc4016"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-025-01276-2"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203158"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1079037"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112488"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Hieronymus H Schultz N Gopalan A et al. Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci USA 2014; 111(30): 11139\u201311144. https:\/\/doi.org\/10.1073\/pnas.1411446111","DOI":"10.1073\/pnas.1411446111"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2025.01.007"},{"issue":"2","key":"e_1_3_3_15_2","first-page":"134","article-title":"The role of genetics in prostate cancer","volume":"23","author":"Carter HB","year":"2020","unstructured":"Carter HB, Gann PH, Epstein JI, et al. The role of genetics in prostate cancer. Prostate Cancer Prostatic Dis 2020; 23(2): 134\u2013142.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"e_1_3_3_16_2","first-page":"235","article-title":"Polygenic risk scores in prostate cancer","volume":"16","author":"Pritchard CC","year":"2019","unstructured":"Pritchard CC, Mateo J, Walsh MF. Polygenic risk scores in prostate cancer. Nat Rev Urol 2019; 16(4): 235\u2013243.","journal-title":"Nat Rev Urol"},{"issue":"6","key":"e_1_3_3_17_2","first-page":"1000","article-title":"Genetic susceptibility to prostate cancer: the role of family history and heritable genetic variants","volume":"29","author":"Amundadottir LT","year":"2020","unstructured":"Amundadottir LT, Gudmundsson J, Gudbjartsson DF, et al. Genetic susceptibility to prostate cancer: the role of family history and heritable genetic variants. Cancer Epidemiol Biomarkers Prev 2020; 29(6): 1000\u20131010.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"e_1_3_3_18_2","first-page":"563","article-title":"BRCA2 mutations in prostate cancer","volume":"6","author":"Rocca A","year":"2020","unstructured":"Rocca A, Tinzl M, Jereczek-Fossa BA, et al. BRCA2 mutations in prostate cancer. JAMA Oncol 2020; 6(4): 563\u2013570.","journal-title":"JAMA Oncol"},{"issue":"18","key":"e_1_3_3_19_2","first-page":"2082","article-title":"The role of ATM mutations in prostate cancer","volume":"38","author":"Giri VN","year":"2020","unstructured":"Giri VN, Knudsen KE, Kelly WK, et al. The role of ATM mutations in prostate cancer. J Clin Oncol 2020; 38(18): 2082\u20132089.","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001"},{"issue":"2","key":"e_1_3_3_21_2","first-page":"163","article-title":"BRCA mutations in prostate cancer and implications for therapy","volume":"77","author":"Mateo J","year":"2020","unstructured":"Mateo J, Boysen G, Barbieri CE, et al. BRCA mutations in prostate cancer and implications for therapy. Eur Urol 2020; 77(2): 163\u2013171.","journal-title":"Eur Urol"},{"issue":"12","key":"e_1_3_3_22_2","first-page":"771","article-title":"Disparities in prostate cancer incidence and outcomes across racial and ethnic groups","volume":"15","author":"Klein EA","year":"2018","unstructured":"Klein EA, Tangen CM, Thompson IM, et al. Disparities in prostate cancer incidence and outcomes across racial and ethnic groups. Nat Rev Urol 2018; 15(12): 771\u2013785.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"e_1_3_3_23_2","first-page":"1140","article-title":"Genetic variants and prostate cancer aggressiveness in African American men","volume":"125","author":"Huo D","year":"2019","unstructured":"Huo D, Jiang X, Zhang X, et al. Genetic variants and prostate cancer aggressiveness in African American men. Cancer 2019; 125(7): 1140\u20131148.","journal-title":"Cancer"},{"key":"e_1_3_3_24_2","first-page":"101891","article-title":"Migration from Asia to Western countries: a change in prostate cancer risk","volume":"69","author":"Chen W","year":"2020","unstructured":"Chen W, Lee C, Chang R, et al. Migration from Asia to Western countries: a change in prostate cancer risk. Cancer Epidemiol 2020; 69: 101891.","journal-title":"Cancer Epidemiol"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2017.08.001"},{"issue":"5","key":"e_1_3_3_26_2","first-page":"1465","article-title":"Lifestyle factors and prostate cancer risk: the role of physical activity","volume":"147","author":"Spector T","year":"2020","unstructured":"Spector T, Green J, Morris J, et al. Lifestyle factors and prostate cancer risk: the role of physical activity. Int J Cancer 2020; 147(5): 1465\u20131473.","journal-title":"Int J Cancer"},{"issue":"1","key":"e_1_3_3_27_2","first-page":"1","article-title":"Obesity and prostate cancer risk: a systematic review of the literature","volume":"146","author":"Agarwal R","year":"2020","unstructured":"Agarwal R, Prasad A, Lee S. Obesity and prostate cancer risk: a systematic review of the literature. Int J Cancer 2020; 146(1): 1\u201315.","journal-title":"Int J Cancer"},{"issue":"10","key":"e_1_3_3_28_2","first-page":"1522","article-title":"Dietary patterns and prostate cancer risk: a systematic review and meta-analysis","volume":"6","author":"Cao Y","year":"2020","unstructured":"Cao Y, Li H, Wang Q, et al. Dietary patterns and prostate cancer risk: a systematic review and meta-analysis. JAMA Oncol 2020; 6(10): 1522\u20131530.","journal-title":"JAMA Oncol"},{"key":"e_1_3_3_29_2","first-page":"22","article-title":"Carcinogens in red and processed meats and their role in prostate cancer risk","volume":"45","author":"Jenkins M","year":"2021","unstructured":"Jenkins M, Patel A, Ray J, et al. Carcinogens in red and processed meats and their role in prostate cancer risk. Cancer Epidemiol 2021; 45: 22\u201330.","journal-title":"Cancer Epidemiol"},{"issue":"7","key":"e_1_3_3_30_2","first-page":"575","article-title":"Lycopene and isoflavones in prostate cancer prevention: a meta-analysis","volume":"14","author":"Vikram A","year":"2021","unstructured":"Vikram A, Sharma M, Kaur A, et al. Lycopene and isoflavones in prostate cancer prevention: a meta-analysis. Cancer Prev Res 2021; 14(7): 575\u2013586.","journal-title":"Cancer Prev Res"},{"issue":"8","key":"e_1_3_3_31_2","first-page":"641","article-title":"Mediterranean diet and risk of prostate cancer","volume":"78","author":"Buck K","year":"2020","unstructured":"Buck K, Wiedermann W, Meisinger C, et al. Mediterranean diet and risk of prostate cancer. Nutr Rev 2020; 78(8): 641\u2013650.","journal-title":"Nutr Rev"},{"issue":"9","key":"e_1_3_3_32_2","first-page":"4545","article-title":"Androgen receptor sensitivity and prostate cancer","volume":"130","author":"Nishida T","year":"2020","unstructured":"Nishida T, Yamashita T, Hasegawa M, et al. Androgen receptor sensitivity and prostate cancer. J Clin Investig 2020; 130(9): 4545\u20134553.","journal-title":"J Clin Investig"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-08-0043"},{"issue":"1","key":"e_1_3_3_34_2","first-page":"1","article-title":"Age as a significant risk factor in prostate cancer","volume":"24","author":"Eisenberg ML","year":"2021","unstructured":"Eisenberg ML, Hotaling JM, Walsh TJ. Age as a significant risk factor in prostate cancer. Prostate Cancer Prostatic Dis 2021; 24(1): 1\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"e_1_3_3_35_2","first-page":"292","article-title":"Chronic prostatitis as a precursor to prostate cancer","volume":"17","author":"Gerber L","year":"2020","unstructured":"Gerber L, Moreira DM, Andriole GL, et al. Chronic prostatitis as a precursor to prostate cancer. Nat Rev Urol 2020; 17(5): 292\u2013305.","journal-title":"Nat Rev Urol"},{"key":"e_1_3_3_36_2","first-page":"82","article-title":"Smoking and prostate cancer outcomes","volume":"141","author":"Schroeder H","year":"2020","unstructured":"Schroeder H, Albers P, Senge T, et al. Smoking and prostate cancer outcomes. Urology 2020; 141: 82\u201390.","journal-title":"Urology"},{"key":"e_1_3_3_37_2","first-page":"102458","article-title":"Advances in the treatment of localized and metastatic prostate cancer","volume":"110","author":"Zhang L","year":"2022","unstructured":"Zhang L, Yang G, Zhao C. Advances in the treatment of localized and metastatic prostate cancer. Cancer Treat Rev 2022; 110: 102458.","journal-title":"Cancer Treat Rev"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02799.x"},{"issue":"3","key":"e_1_3_3_39_2","first-page":"168","article-title":"Response and resistance to docetaxel in metastatic castration-resistant prostate cancer","volume":"18","author":"Al Nakouzi N","year":"2021","unstructured":"Al Nakouzi N, Le Moulec S, Albiges L, et al. Response and resistance to docetaxel in metastatic castration-resistant prostate cancer. Nat Rev Urol 2021; 18(3): 168\u2013184.","journal-title":"Nat Rev Urol"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1466"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315815"},{"issue":"11","key":"e_1_3_3_43_2","first-page":"657","article-title":"Molecular mechanisms of resistance in prostate cancer","volume":"17","author":"Gurel B","year":"2020","unstructured":"Gurel B, Iwata T, Koh CM, et al. Molecular mechanisms of resistance in prostate cancer. Nat Rev Urol 2020; 17(11): 657\u2013674.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"e_1_3_3_44_2","first-page":"60","article-title":"The role of the microenvironment in prostate cancer progression and therapy resistance","volume":"18","author":"Jiang Y","year":"2019","unstructured":"Jiang Y, Zhang Q, Liu H, et al. The role of the microenvironment in prostate cancer progression and therapy resistance. Mol Cancer 2019; 18(1): 60.","journal-title":"Mol Cancer"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2012.07.012"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.529"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13512"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1177\/15330338211011965"},{"issue":"1","key":"e_1_3_3_49_2","first-page":"17","article-title":"Targeting the androgen receptor via PROTACs in prostate cancer","volume":"18","author":"Schenone M","year":"2021","unstructured":"Schenone M, Wang Y, Liu Y, et al. Targeting the androgen receptor via PROTACs in prostate cancer. Nat Rev Urol 2021; 18(1): 17\u201330.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"e_1_3_3_50_2","first-page":"623","article-title":"EZH2 inhibition reprograms resistant prostate cancer to respond to immunotherapy","volume":"82","author":"Zhang Q","year":"2022","unstructured":"Zhang Q, Wang J, Xu M, et al. EZH2 inhibition reprograms resistant prostate cancer to respond to immunotherapy. Cancer Res 2022; 82(4): 623\u2013635.","journal-title":"Cancer Res"},{"issue":"3","key":"e_1_3_3_51_2","first-page":"689","article-title":"PSMA-directed CAR-T therapy for prostate cancer: advances and challenges","volume":"27","author":"Narayan V","year":"2021","unstructured":"Narayan V, Wang T, Li Y, et al. PSMA-directed CAR-T therapy for prostate cancer: advances and challenges. Clin Cancer Res 2021; 27(3): 689\u2013696.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_52_2","doi-asserted-by":"crossref","unstructured":"de Bono J Mateo J Fizazi K et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020; 382(22): 2091\u20132102. https:\/\/doi.org\/10.1056\/NEJMoa1911440","DOI":"10.1056\/NEJMoa1911440"},{"key":"e_1_3_3_53_2","first-page":"114004","article-title":"Nanoparticle-mediated drug delivery systems for overcoming resistance in prostate cancer","volume":"200","author":"Cheng Y","year":"2023","unstructured":"Cheng Y, Tan W, Liu Y, et al. Nanoparticle-mediated drug delivery systems for overcoming resistance in prostate cancer. Adv Drug Deliv Rev 2023; 200: 114004.","journal-title":"Adv Drug Deliv Rev"},{"key":"e_1_3_3_54_2","doi-asserted-by":"crossref","unstructured":"Hasin Y Seldin M Lusis A. Multi-omics approaches to disease. Genome Biol 2017; 18: 83. https:\/\/doi.org\/10.1186\/s13059-017-1215-1","DOI":"10.1186\/s13059-017-1215-1"},{"key":"e_1_3_3_55_2","unstructured":"Abida W Cyrta J Heller G et al. Genomic correlates of clinical outcome in advanced prostate cancer. Cancer Discov 2023; 13(1): 100\u2013115. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0915"},{"key":"e_1_3_3_56_2","doi-asserted-by":"crossref","unstructured":"Stopsack KH Mucci LA Antonarakis ES et al. Prostate cancer. Nat Rev Clin Oncol 2020; 17(11): 645\u2013661. https:\/\/doi.org\/10.1038\/s41571-020-0363-0","DOI":"10.1038\/s41571-020-0395-x"},{"key":"e_1_3_3_57_2","unstructured":"Mateo J Porta N Bianchini D et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): A multicentre open-label randomised phase 2 trial. J Clin Oncol 2022; 40(28): 3184\u20133193. https:\/\/doi.org\/10.1200\/JCO.21.01503"},{"key":"e_1_3_3_58_2","doi-asserted-by":"crossref","unstructured":"Teply BA Patel HD Trock BJ et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: An open-label phase 2 multicohort study. J Natl Compr Canc Netw 2021; 19(2): 141\u2013149. https:\/\/doi.org\/10.6004\/jnccn.2020.7557","DOI":"10.6004\/jnccn.2020.7557"},{"key":"e_1_3_3_59_2","unstructured":"Aggarwal R Xie Z Bryant TT et al. MET alterations are associated with aggressive features and poor outcomes in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2023; 29(5): 951\u2013961. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2281"},{"key":"e_1_3_3_60_2","doi-asserted-by":"crossref","unstructured":"Bluemn EG Coleman IM Lucas JM et al. Androgen receptor pathway\u2013independent prostate cancer is sustained through FGF signaling. Nat Med 2017; 23(5): 632\u2013639. https:\/\/doi.org\/10.1038\/nm.4326","DOI":"10.1038\/nm.4326"},{"key":"e_1_3_3_61_2","unstructured":"Aggarwal R Huang J Alumkal JJ et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study. J Clin Investig 2018; 128(2): 123\u2013135. https:\/\/doi.org\/10.1172\/JCI97024"},{"key":"e_1_3_3_62_2","unstructured":"Chen W Zhang L Yang Y et al. Multimodal single-cell analysis reveals distinct tumor microenvironment in antiandrogen resistance. Cell Rep Med 2023; 4(2): 100930. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100930"},{"key":"e_1_3_3_63_2","doi-asserted-by":"crossref","unstructured":"Scher HI Lu D Schreiber NA et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2016; 2(11): 1441\u20131449. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1828","DOI":"10.1001\/jamaoncol.2016.1828"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28627"},{"key":"e_1_3_3_65_2","doi-asserted-by":"crossref","unstructured":"Latonen L Afyounian E Jylh\u00e4 A et al. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun 2018; 9(1): 1176. https:\/\/doi.org\/10.1038\/s41467-018-03573-6","DOI":"10.1038\/s41467-018-03573-6"},{"key":"e_1_3_3_66_2","unstructured":"Kim W Zhang X Ramesh N. Resistance mechanisms to androgen receptor inhibitors in prostate cancer and strategies to overcome resistance. Nat Rev Urol 2022; 19(8): 487\u2013505. https:\/\/doi.org\/10.1038\/s41585-022-00632-4"},{"key":"e_1_3_3_67_2","doi-asserted-by":"crossref","unstructured":"Doll S Freitas FP Shah R et al. FSP1 is a glutathione-independent ferroptosis suppressor. Cancer Cell 2020; 38(3): 306\u2013319.e7. https:\/\/doi.org\/10.1016\/j.ccell.2020.06.005","DOI":"10.1016\/j.ccell.2020.06.005"},{"key":"e_1_3_3_68_2","unstructured":"Lin D Wyatt AW Xue H et al. High fidelity patient-derived xenografts for predicting clinical outcomes in prostate cancer. Clin Cancer Res 2023; 29(3): 625\u2013637. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2039"},{"key":"e_1_3_3_69_2","unstructured":"Kaushik AK Shoag J De Marzo AM. Genomic alterations in prostate cancer and their clinical implications. Nat Rev Urol 2021; 18(7): 365\u2013380. https:\/\/doi.org\/10.1038\/s41585-021-00452-4"},{"key":"e_1_3_3_70_2","doi-asserted-by":"crossref","unstructured":"Santana-Codina N Mancias JD Kimmelman AC et al. Pancreatic and prostate cancer metabolism: A comparative perspective. Cell Metab 2022; 34(4): 547\u2013567.e6. https:\/\/doi.org\/10.1016\/j.cmet.2022.03.003","DOI":"10.1016\/j.cmet.2022.03.003"},{"key":"e_1_3_3_71_2","unstructured":"Wang Y Huang D Zhang J et al. Tumor immune microenvironment landscape and immune-related biomarkers in prostate cancer. Cancer Res 2023; 83(1): 102\u2013115. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-1234"},{"key":"e_1_3_3_72_2","unstructured":"Gorugantu SR Singh RK Sharma A et al. Dual inhibition of PI3K and androgen receptor pathways in prostate cancer: preclinical rationale and therapeutic implications. Mol Cancer Ther 2023; 22(2): 178\u2013189. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0458"},{"key":"e_1_3_3_73_2","unstructured":"Wibmer AG Vargas HA Donoghue M et al. Quantitative18F-DCFPyL PET\/CT metrics for detecting disease progression in metastatic castration-resistant prostate cancer. Radiology 2021; 298(3): 521\u2013531. https:\/\/doi.org\/10.1148\/radiol.2021202485"},{"issue":"5","key":"e_1_3_3_74_2","first-page":"566","article-title":"Prostate cancer stem cells and implications for cancer therapy","volume":"3","author":"Stoyanova T","year":"2020","unstructured":"Stoyanova T, Cooper TE, Drake JM, et al. Prostate cancer stem cells and implications for cancer therapy. Eur Urol Oncol 2020; 3(5): 566\u2013576. DOI provided upon request.","journal-title":"Eur Urol Oncol"},{"key":"e_1_3_3_75_2","unstructured":"Hicks RM Bauman G Beltran H et al. The role of imaging in managing prostate cancer: consensus statement from the Advanced prostate cancer consensus conference. J Nucl Med 2022; 63(3): 360\u2013367. https:\/\/doi.org\/10.2967\/jnumed.121.263981"},{"key":"e_1_3_3_76_2","unstructured":"Wang Z Liu Z Li T et al. Molecular imaging of PSMA and GRPR in prostate cancer: diagnostic and therapeutic potential. Cancer Imaging 2023; 23(1): 15. https:\/\/doi.org\/10.1186\/s40644-023-00534-6"},{"key":"e_1_3_3_77_2","unstructured":"Gupta S Patel K Dahiya R. DNA methylation and chromatin remodeling in prostate cancer. Nat Rev Urol 2021; 18(5): 309\u2013324. https:\/\/doi.org\/10.1038\/s41585-021-00431-9"},{"key":"e_1_3_3_78_2","doi-asserted-by":"crossref","unstructured":"Pomerantz MM Qiu X Zhu Y et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet 2020; 52(8): 790\u2013799. https:\/\/doi.org\/10.1038\/s41588-020-0664-8","DOI":"10.1038\/s41588-020-0664-8"},{"key":"e_1_3_3_79_2","unstructured":"Chen H Pan D Ma Y et al. Spatial transcriptomics and single-cell genomics reveal immune microenvironment heterogeneity in prostate cancer. Cancer Discov 2023; 13(1): 145\u2013163. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0580"},{"key":"e_1_3_3_80_2","unstructured":"Beltran H Sboner A Demichelis F et al. New strategies in prostate cancer: translating genomic insights into clinical practice. J Clin Oncol 2022; 40(9): 1001\u20131013. https:\/\/doi.org\/10.1200\/JCO.21.02226"},{"key":"e_1_3_3_81_2","unstructured":"Sowalsky AG Ye H Bango C et al. Molecular determinants of resistance to enzalutamide in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2022; 28(2): 317\u2013329. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2073"},{"key":"e_1_3_3_82_2","unstructured":"Sharma NL Kothari V Palanisamy N et al. Chromatin architecture and transcriptional regulation in prostate cancer. Nat Rev Urol 2022; 19(6): 350\u2013364. https:\/\/doi.org\/10.1038\/s41585-022-00638-y"},{"key":"e_1_3_3_83_2","unstructured":"Jia L Wang Y Wu Y. m6A modification and its role in prostate cancer progression. Cancer Res 2022; 82(3): 489\u2013503. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1805"},{"key":"e_1_3_3_84_2","unstructured":"Gao D Vela I Sboner A et al. Dissecting spatial heterogeneity in prostate cancer by single-cell multiomics and spatial transcriptomics. Nat Commun 2023; 14(1): 1122. https:\/\/doi.org\/10.1038\/s41467-023-36759-3"},{"key":"e_1_3_3_85_2","volume-title":"Guidelines for the Management of Prostate Cancer","author":"ASCO","year":"2021","unstructured":"ASCO. Guidelines for the Management of Prostate Cancer. ASCO, 2021."},{"key":"e_1_3_3_86_2","volume-title":"Prostate Cancer Treatment Guidelines","author":"NCCN","year":"2021","unstructured":"NCCN. Prostate Cancer Treatment Guidelines. NCCN, 2021."},{"issue":"3","key":"e_1_3_3_87_2","first-page":"351","article-title":"Prostate-specific membrane antigen (PSMA)-based imaging in prostate cancer","volume":"61","author":"Rahbar K","year":"2020","unstructured":"Rahbar K, Afshar-Oromieh A, Giesel FL, et al. Prostate-specific membrane antigen (PSMA)-based imaging in prostate cancer. J Nucl Med 2020; 61(3): 351\u2013358.","journal-title":"J Nucl Med"},{"issue":"5","key":"e_1_3_3_88_2","first-page":"768","article-title":"Prostate cancer imaging with PSMA PET","volume":"78","author":"Hofman MS","year":"2020","unstructured":"Hofman MS, Violet J, Hicks RJ, et al. Prostate cancer imaging with PSMA PET. Eur Urol 2020; 78(5): 768\u2013776.","journal-title":"Eur Urol"},{"issue":"3","key":"e_1_3_3_89_2","first-page":"432","article-title":"Sarcosine and prostate cancer recurrence","volume":"22","author":"Vessella RL","year":"2019","unstructured":"Vessella RL, Rhodes DR, Mach K, et al. Sarcosine and prostate cancer recurrence. Prostate Cancer Prostatic Dis 2019; 22(3): 432\u2013440.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01393-9"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.893424"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-025-09543-7"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.5152\/eurasianjmed.2025.25828"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-690"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.06.009"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07762"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189971"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2018.04.001"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3419"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261457521","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603261457521","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261457521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T07:06:57Z","timestamp":1792307217000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603261457521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1177\/03915603261457521"],"URL":"https:\/\/doi.org\/10.1177\/03915603261457521","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}